UNDERWRITING AGREEMENT SEATTLE GENETICS, INC. 11,538,461 Shares of Common Stock Underwriting AgreementUnderwriting Agreement • February 1st, 2018 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • New York
Pursuant to that certain Agreement and Plan of Merger, dated as of January 30, 2018 (the “Acquisition Agreement”), by and among the Company, Valley Acquisition Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Company (“Merger Sub”), and Cascadian Therapeutics, Inc., a Delaware corporation (“Cascadian”), Merger Sub will acquire all of the outstanding equity of Cascadian pursuant to a tender offer followed by a merger of Merger Sub into Cascadian, following which Cascadian will survive as an indirect, wholly owned subsidiary of the Company (the “Merger”). The offering is not contingent on the consummation of the Merger.
